Sprint Corporation (NYSE:S)
Sprint Corporation offers communications services. It operates in two segments: Wireless and Wireline. It develops, engineers and deploys technologies, including wireless networks offering mobile data services, instant national and international push-to-talk capabilities and a global Tier 1 Internet backbone. Sprint Corporation is based in Overland Park, United States.
Sprint Corporation (NYSE:S)’s Financial Overview
Sprint Corporation (NYSE) surged 0% yesterday to close its trading session at $5.9. The company has 1 year Price Target of $5.83. Sprint Corporation has 52-Week high of $6.62 and 52-Week Low of $4.81. The stock touched its 52-Week High on 6.62 and 52-Week Low on 4.81. The stock traded with the volume of 16.71 Million shares yesterday. The firm shows the market capitalization of $24.07 Billion.
Sprint Corporation (NYSE) reported its last quarterly earnings on 12/30/2018 where the firm reported its Actual EPS of $-0.03/share against the analyst consensus estimate of $-0.02/share. The difference between the actual and expected EPS is $-0.01 a share with a surprise factor of -50%.
The firm is trading with SMA20 of -3.42 Percent, SMA50 of -2.84 Percent and SMA200 of 0.15 percent. Sprint Corporation has P/S value of 0.72 while its P/B value stands at 0.85. Similarly, the company has Return on Assets of 0.3 percent, Return on Equity of 1.1 percent and Return on Investment of 3.9 Percent. The company shows Gross Margin and Operating Margin of 59 percent and 6.9 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 3.1 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 17 analysts offering 12-month price forecasts for Sprint Corp have a median target of 6.00, with a high estimate of 8.50 and a low estimate of 4.50. The median estimate represents a +1.69% increase from the last price of 5.90.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
Dermira, Inc. (NASDAQ:DERM)
Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California.
Dermira, Inc. (NASDAQ:DERM)’s Financial Outlook
The 6 analysts offering 12-month price forecasts for Dermira Inc have a median target of 18.00, with a high estimate of 25.00 and a low estimate of 9.00. The median estimate represents a +165.10% increase from the last price of 6.79.
Dermira, Inc. is estimated to report earnings on 02/28/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-1.8. The reported EPS for the same quarter last year was $-1.34.
According to Zacks Investment Research, Dermira, Inc. has a Consensus Recommendation of 1.8. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock declined -2.02% and closed its last trading session at $6.79. The company has the market capitalization of $291.9 Million. The stock has 52-week high of $29.18 and 52-Week low of $6. The firm touched its 52-Week high on 29.18 and 52-Week low on 6.00. The company has volume of 329070 shares. The company has a total of 42.99 Million shares outstanding.
Dermira, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-1.58/share where the analyst estimated EPS was $-1.63/share. The difference between the actual and Estimated EPS is $0.05. This shows a surprise factor of 3.1 percent.
The company has YTD performance of -5.56 percent. Beta for Dermira, Inc. stands at 1.25 while its ATR (average true range) is 0.44. The company has Weekly Volatility of 6.24%% and Monthly Volatility of 6.50%%.
Dermira, Inc. has distance from 20-day Simple Moving Average (SMA20) of 0.1%, Distance from 50-Day Simple Moving Average of -17.79 percent and Distance from 200-Day Simple Moving Average of -31.12%.
